Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma

The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology, Immunotherapy Immunotherapy, 2018-06, Vol.67 (6), p.925-933
Hauptverfasser: van den Brom, Rob R. H., van der Geest, Kornelis S. M., Brouwer, Elisabeth, Hospers, Geke A. P., Boots, Annemieke M. H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 933
container_issue 6
container_start_page 925
container_title Cancer Immunology, Immunotherapy
container_volume 67
creator van den Brom, Rob R. H.
van der Geest, Kornelis S. M.
Brouwer, Elisabeth
Hospers, Geke A. P.
Boots, Annemieke M. H.
description The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3 high memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3 low naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients.
doi_str_mv 10.1007/s00262-018-2148-6
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5951899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2015634540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</originalsourceid><addsrcrecordid>eNp1kUFv1DAQhS1ERZfCD-CCLHFBQiljx3HsC1K1LVCpEhzK2XJsZzclsRfbKeyJv46jLS0gcfJo5pvneXoIvSBwSgDatwmAcloBERUlTFT8EVoRVpeOaMhjtIKaQdUCsGP0NKWbUlCQ8gk6prJhnNXNCv288FvtjbPY_dhFl9IQPA49_nxeEay9xSFvXcTa5OFW52U46fjVxYS7PV6fszf4Ghs3jmlZ2ofZb3A3Z-xDxmG0eFd2nM8Jfx_yFk8u65RLy5Ry1D5M-hk66vWY3PO79wR9eX9xvf5YXX36cLk-u6oMayFXwmhtqRakN5JzI0kNNZBe2t4YLsA2bceMsIQ53THaGw28k4S71grNe5D1CXp30N3N3eSsKUdFPapdHIqfvQp6UH9P_LBVm3CrGtkQIReB13cCMXybXcpqGtLiXHsX5qQoECaZlIwX9NU_6E2Yoy_2FqrhNWsYFIocKBNDStH198cQUEu86hCvKvGqJV61KL_808X9xu88C0APQCojv3Hx4ev_q_4C7BWxmw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2015634540</pqid></control><display><type>article</type><title>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>van den Brom, Rob R. H. ; van der Geest, Kornelis S. M. ; Brouwer, Elisabeth ; Hospers, Geke A. P. ; Boots, Annemieke M. H.</creator><creatorcontrib>van den Brom, Rob R. H. ; van der Geest, Kornelis S. M. ; Brouwer, Elisabeth ; Hospers, Geke A. P. ; Boots, Annemieke M. H.</creatorcontrib><description>The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3 high memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3 low naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-018-2148-6</identifier><identifier>PMID: 29546435</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Age ; Age Factors ; Cancer Research ; Case-Control Studies ; CD4 antigen ; CD4-Positive T-Lymphocytes - immunology ; CD45RA antigen ; CD8 antigen ; Cell activation ; Female ; Geriatrics ; Histocompatibility antigen HLA ; Humans ; Immunological memory ; Immunology ; Immunoregulation ; Lymphocytes ; Lymphocytes T ; Male ; Medicine ; Medicine &amp; Public Health ; Melanoma ; Melanoma - blood ; Melanoma - immunology ; Melanoma - pathology ; Memory cells ; Metastases ; Metastasis ; Middle Aged ; Oncology ; Original ; Original Article ; PD-1 protein ; Physicians ; Programmed Cell Death 1 Receptor - biosynthesis ; Programmed Cell Death 1 Receptor - immunology ; T cell receptors</subject><ispartof>Cancer Immunology, Immunotherapy, 2018-06, Vol.67 (6), p.925-933</ispartof><rights>The Author(s) 2018</rights><rights>Cancer Immunology, Immunotherapy is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</citedby><cites>FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951899/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951899/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29546435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van den Brom, Rob R. H.</creatorcontrib><creatorcontrib>van der Geest, Kornelis S. M.</creatorcontrib><creatorcontrib>Brouwer, Elisabeth</creatorcontrib><creatorcontrib>Hospers, Geke A. P.</creatorcontrib><creatorcontrib>Boots, Annemieke M. H.</creatorcontrib><title>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3 high memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3 low naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients.</description><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Cancer Research</subject><subject>Case-Control Studies</subject><subject>CD4 antigen</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD45RA antigen</subject><subject>CD8 antigen</subject><subject>Cell activation</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Immunological memory</subject><subject>Immunology</subject><subject>Immunoregulation</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Melanoma</subject><subject>Melanoma - blood</subject><subject>Melanoma - immunology</subject><subject>Melanoma - pathology</subject><subject>Memory cells</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>PD-1 protein</subject><subject>Physicians</subject><subject>Programmed Cell Death 1 Receptor - biosynthesis</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>T cell receptors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUFv1DAQhS1ERZfCD-CCLHFBQiljx3HsC1K1LVCpEhzK2XJsZzclsRfbKeyJv46jLS0gcfJo5pvneXoIvSBwSgDatwmAcloBERUlTFT8EVoRVpeOaMhjtIKaQdUCsGP0NKWbUlCQ8gk6prJhnNXNCv288FvtjbPY_dhFl9IQPA49_nxeEay9xSFvXcTa5OFW52U46fjVxYS7PV6fszf4Ghs3jmlZ2ofZb3A3Z-xDxmG0eFd2nM8Jfx_yFk8u65RLy5Ry1D5M-hk66vWY3PO79wR9eX9xvf5YXX36cLk-u6oMayFXwmhtqRakN5JzI0kNNZBe2t4YLsA2bceMsIQ53THaGw28k4S71grNe5D1CXp30N3N3eSsKUdFPapdHIqfvQp6UH9P_LBVm3CrGtkQIReB13cCMXybXcpqGtLiXHsX5qQoECaZlIwX9NU_6E2Yoy_2FqrhNWsYFIocKBNDStH198cQUEu86hCvKvGqJV61KL_808X9xu88C0APQCojv3Hx4ev_q_4C7BWxmw</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>van den Brom, Rob R. H.</creator><creator>van der Geest, Kornelis S. M.</creator><creator>Brouwer, Elisabeth</creator><creator>Hospers, Geke A. P.</creator><creator>Boots, Annemieke M. H.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180601</creationdate><title>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</title><author>van den Brom, Rob R. H. ; van der Geest, Kornelis S. M. ; Brouwer, Elisabeth ; Hospers, Geke A. P. ; Boots, Annemieke M. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Cancer Research</topic><topic>Case-Control Studies</topic><topic>CD4 antigen</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD45RA antigen</topic><topic>CD8 antigen</topic><topic>Cell activation</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Immunological memory</topic><topic>Immunology</topic><topic>Immunoregulation</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Melanoma</topic><topic>Melanoma - blood</topic><topic>Melanoma - immunology</topic><topic>Melanoma - pathology</topic><topic>Memory cells</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>PD-1 protein</topic><topic>Physicians</topic><topic>Programmed Cell Death 1 Receptor - biosynthesis</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>T cell receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van den Brom, Rob R. H.</creatorcontrib><creatorcontrib>van der Geest, Kornelis S. M.</creatorcontrib><creatorcontrib>Brouwer, Elisabeth</creatorcontrib><creatorcontrib>Hospers, Geke A. P.</creatorcontrib><creatorcontrib>Boots, Annemieke M. H.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van den Brom, Rob R. H.</au><au>van der Geest, Kornelis S. M.</au><au>Brouwer, Elisabeth</au><au>Hospers, Geke A. P.</au><au>Boots, Annemieke M. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>67</volume><issue>6</issue><spage>925</spage><epage>933</epage><pages>925-933</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3 high memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3 low naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29546435</pmid><doi>10.1007/s00262-018-2148-6</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology, Immunotherapy, 2018-06, Vol.67 (6), p.925-933
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5951899
source MEDLINE; Springer Nature - Complete Springer Journals; PubMed Central
subjects Adult
Age
Age Factors
Cancer Research
Case-Control Studies
CD4 antigen
CD4-Positive T-Lymphocytes - immunology
CD45RA antigen
CD8 antigen
Cell activation
Female
Geriatrics
Histocompatibility antigen HLA
Humans
Immunological memory
Immunology
Immunoregulation
Lymphocytes
Lymphocytes T
Male
Medicine
Medicine & Public Health
Melanoma
Melanoma - blood
Melanoma - immunology
Melanoma - pathology
Memory cells
Metastases
Metastasis
Middle Aged
Oncology
Original
Original Article
PD-1 protein
Physicians
Programmed Cell Death 1 Receptor - biosynthesis
Programmed Cell Death 1 Receptor - immunology
T cell receptors
title Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T01%3A10%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20expression%20of%20PD-1%20and%20other%20activation%20markers%20by%20CD4+%20T%20cells%20of%20young%20but%20not%20old%20patients%20with%20metastatic%20melanoma&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=van%20den%20Brom,%20Rob%20R.%20H.&rft.date=2018-06-01&rft.volume=67&rft.issue=6&rft.spage=925&rft.epage=933&rft.pages=925-933&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-018-2148-6&rft_dat=%3Cproquest_pubme%3E2015634540%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2015634540&rft_id=info:pmid/29546435&rfr_iscdi=true